

PATENT

Please amend the following claims:

1. A therapeutic agent for myocardiodopathy used for noninvasive administration, comprising a therapeutically effective amount of a nucleic acid molecule encoding a hepatocyte growth factor (HGF).
2. The therapeutic agent of claim 1, wherein the nucleic acid molecule is a pharmaceutical composition suitable for administration into cardiac muscle.
3. The therapeutic agent of claim 1, wherein the nucleic acid molecule comprises a Sendai virus (HVJ)-liposome.
4. The therapeutic agent of claim 2, wherein noninvasive administration comprises echocardiography guided administration.
5. The therapeutic agent of claim 1, wherein the agent is administered once a week for 8 weeks.
6. The therapeutic agent of claim 1, comprising at least 10 μ g of the nucleic acid molecule.
7. The therapeutic agent of claim 1, wherein the myocardiodopathy is selected from the group consisting of cardiomyopathy, angina pectoris and heart failure.
8. A therapeutic agent used for noninvasive administration of a nucleic acid molecule into an affected part of a tissue using echocardiography, comprising a therapeutically effective amount of a nucleic acid molecule encoding a polypeptide effective for the treatment of a disorder.
9. The agent of claim 8, wherein the affected part of the tissue is cardiac muscle.
10. The agent of claim 8, wherein the nucleic acid molecule encodes HGF.

PATENT

11. A method for treating myocardial pathology, comprising noninvasive administration of a therapeutically effective amount of a nucleic acid molecule encoding HGF into the cardiac muscle of a mammal.

12. The method of claim 11, wherein the nucleic acid molecule comprises a Sendai virus (HVJ)-liposome.

13. The method of claim 11, wherein the nucleic acid molecule is administered noninvasively to a part of an affected cardiac muscle using echocardiography.

14. The method of claim 11, wherein the nucleic acid molecule is administered once a week for 8 weeks.

15. The method of claim 11, wherein the myocardial pathology is selected from the group consisting of cardiomyopathy, angina pectoris and heart failure.

16. A method for treating a disorder, comprising noninvasive administration of a nucleic acid molecule encoding a polypeptide effective for the treatment of a disorder into an affected part of a tissue using echocardiography.

17. The method of claim 16, wherein the affected tissue is cardiac muscle.

18. The method of claim 16, wherein the nucleic acid molecule encodes HGF.

Please cancel claims 19-25.

Please add the following new claims:

26. The therapeutic agent of claim 2, wherein the nucleic acid molecule comprises a Sendai virus (HVJ)-liposome.

PATENT

27. The therapeutic agent of claim 3, wherein noninvasive administration comprises echocardiography guided administration.

28. The agent of claim 9, wherein the nucleic acid molecule encodes HGF.

29. The method of claim 11, wherein the mammal is a human.

30. The method of claim 12, wherein the nucleic acid molecule is administered noninvasively to a part of an affected cardiac muscle using echocardiography.

31. The method of claim 17, wherein the nucleic acid molecule encodes HGF.

32. The method of claim 11, wherein the noninvasive administration comprises administering the nucleic acid molecule by injection.

33. The method of claim 11, wherein the non evasive administration comprises administering the nucleic acid molecule through a catheter.

34. The method of claim 32, wherein injection comprises injection into an affected cardiac muscle.

35. The method of claim 34, wherein the noninvasive administration further comprises injecting the nucleic acid molecule into the cardiac muscle.

REMARKS

Applicants have amended the specification to introduce the priority claims. Applicants have amended the claims to remove multiple dependencies and revise some of the language of the claims to be more consistent with United States claim drafting style. No new matter has been added by this amendment.